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Capsule 
Background: Decorin antagonizes multiple receptor 
tyrosine kinases, such as Met, to suppress 
tumorigenesis. 
Results: Decorin promotes angiostasis by blocking 
HIF-1α and β-catenin to inhibit VEGFA and MMP2/9 
activity concurrent with thrombospondin-1 and TIMP3 
induction. 
Conclusion: Decorin abrogates the pro-angiogenic 
HGF/Met signaling axis, thereby repressing VEGFA-
mediated angiogenesis under normoxia. 
Significance: Soluble decorin attenuates early tumor 
growth by preventing normoxic angiogenic signaling 
through the Met receptor.  
 
Decorin, a small leucine-rich proteoglycan, inhibits 
tumor growth by antagonizing multiple receptor 
tyrosine kinases including EGFR and Met. Here, we 
investigated decorin during normoxic angiogenic 
signaling. An angiogenic PCR array revealed a 
profound decorin-evoked transcriptional inhibition 
of pro-angiogenic genes, such as HIF1A. Decorin 
evoked a reduction of HIF-1α and VEGFA in MDA-
231 breast carcinoma cells expressing constitutively-
active HIF-1α. Suppression of Met with decorin or 
siRNA evoked a similar reduction of VEGFA by 
attenuating downstream β-catenin signaling. These 
data establish a non-canonical role for β-catenin in 
regulating VEGFA expression. We found that 
exogenous decorin induced expression of 
thrombospondin-1 and TIMP3, two powerful 
angiostatic agents. In contrast, decorin suppressed 
both the expression and enzymatic activity of MMP9 
and MMP2, two pro-angiogenic proteases.  Our data 
establish a novel duality for decorin as a suppressor 
of tumor angiogenesis under normoxia by 
simultaneously down-regulating potent pro-
angiogenic factors and inducing endogenous anti-
angiogenic agents. 
 
A pertinent concept in the field of tumorigenesis is the 
critical role of the extracellular matrix as an active 
participant in the regulation of diverse cell processes 
and signaling events that form an environment signified 
by ever-changing flux (1). These diverse cellular 
processes, permissive for tumor progression, are often 
modulated by matrix constituents that culminate to 
affect tumor invasion, metastasis and angiogenesis (2). 
Various members of the proteoglycan gene family 
are intimately involved in regulating tumor 
angiogenesis by directly affecting key downstream 
signaling pathways via interaction with ligands and 
their cognate receptors (3-5). Decorin, a prototypical 
member belonging to a superfamily of 18 individually-
encoded gene products collectively known as the small 
leucine-rich proteoglycans (SLRPs)2 (6-8), has been 
implicated in regulating angiogenesis.  
Decorin was originally characterized to bind fibrillar 
collagen, primarily type I, and to regulate fibrillogenesis 
(9-16), tissue mechanical properties (17-21), and wound 
healing and fibrosis (22,23). Decorin also regulates the 
entry of Borrelia burgodferi spirochetes–the causative 
agent of Lyme disease–into the dermis (24,25) and 
several other pathophysiological processes including 
dentin and bone mineralization (26-28), skeletal muscle 
homeostasis (29), vertebrate convergent extension (30), 
bone marrow stromal cell fate (31), myocardial 
infarction (32), corneal transparency (33),  various types 
of nephropathies (34-38), and tumor inflammation (39). 
 In the context of cancer, decorin was first identified 
as a proteoglycan highly induced in the stroma of colon 
cancer (40,41) suggesting that decorin might counteract 
the growth of malignant cells in a paracrine fashion. 
Subsequently, it was discovered that decorin evokes 
downregulation of multiple receptor tyrosine kinases 
(RTKs) including the EGFR (42-45) as well as to other 
ErbB family members (46). This signaling leads to 
marked tumor growth inhibition (47), induction of the 
cyclin-dependent kinase inhibitor p21WAF1/CIP1 (p21) 
(48,49) and mobilization of intracellular Ca2+ stores in 
cancer cells (50). Moreover, decorin has been found to 
 1
                                                       Decorin Antagonizes Angiogenesis                           
 2
antagonize the Met proto-oncogene (51) by receptor 
internalization via caveolar-mediated endocytosis (52), 
resulting in cessation of signaling analogous to EGFR 
(53). This mode of action is in stark contrast to clathrin-
mediated endocytosis of Met (54) which enables Met to 
maintain a prolonged activation of downstream 
signaling (55). 
Although decorin-null mice are apparently normal 
(9), double mutant mice lacking decorin and p53 
succumb very early to very aggressive lymphomas 
suggesting that loss of decorin is permissive for 
tumorigenesis (56). This concept is further corroborated 
by a recent study using decorin-null mice in a different 
genetic background. Under these conditions, lack of 
decorin causes intestinal tumor formation, a process 
exacerbated by exposing the mice to a high-fat diet 
(57). Conversely, delivery of decorin gene or protein 
retards the growth of a variety of cancers (58-65). 
The role of decorin in tumor angiogenesis is 
controversial. Previous reports have delineated a pro-
angiogenic response, primarily on normal, non-
tumorigenic endothelial cells (66-68) or through loss of 
decorin in the cornea (69). Interestingly, an anti-
angiogenic role for decorin has also been described in 
various settings (70-72) and as an angiostatic agent 
targeting tumor cells which exhibit dysregulated 
angiogenesis via a reduction in vascular endothelial 
growth factor (VEGF) production (73). The apparent 
dichotomous effects reported for decorin on endothelial 
cells and the perceived function on the tumor itself 
creates a scenario where decorin is able to differentially 
modulate angiogenesis. This is further substantiated by 
a recent report where the expression of decorin was 
evaluated as a function of tumor malignancy. Sarcomas 
exhibited almost a complete absence of decorin in 
contrast to hemangiomas, where decorin was 
predominantly detected in the surrounding stroma (74). 
Aside from the potent pro-migratory, pro-invasive, and 
pro-survival roles inherent with aberrant Met activation 
(75), the Met signaling axis is powerfully pro-
angiogenic, specifically promoting VEGFA mediated 
angiogenesis (76,77). These observations coupled to the 
discovery of rapid and sustained physical 
downregulation of Met evoked by nanomolar 
concentrations of recombinant decorin  (51,52) led us to 
hypothesize that decorin could inhibit angiogenesis via 
downregulation of the Met signaling axis.   
In the present study, we provide mechanistic insight 
supporting a functional link between decorin and the 
Met signaling axis vis-á-vis the regulation of 
pathological VEGF-mediated angiogenesis. The 
angiostatic effects resulting in a marked inhibition of 
VEGFA occur at both the transcriptional and post-
transcriptional levels with upstream signaling occurring 
via Met, which is antagonized by decorin. Further, our 
findings indicate a novel induction of thrombospondin-
1 and TIMP3, coincident with the suppression of pro-
angiogenic molecules. Thus, our data reinforce and 
extend the critical role for decorin as an antagonist of 
tumor angiogenesis. 
 
EXPERIMENTAL PROCEDURES 
Cells and Materials—HeLa squamous carcinoma and 
MDA-MB-231 triple-negative breast carcinoma cells 
were obtained from American Type Culture Collection 
(Manassas, VA). MDA-MB-231 (hereafter referred to 
as MDA-231 including derivative MDA-231 cell lines), 
MDA-231(GFP+), wtHIF-1α and mutHIF-1α cells 
were previously described (78). Cells were maintained 
in Dulbecco’s Modified Eagle’s Medium supplemented 
with 10% fetal bovine serum (FBS) (SAFC 
Biosciences, Lenexa, KS) as well as with 100 μg/ml of 
penicillin/streptomycin (MediaTech, Manassas, VA). 
Human umbilical vein endothelial cells (HUVECs) 
were purchased from Lifeline cells Technology 
(Walkersville, MD) and used only within the first 5 
passages. Primary antibodies against VEGFA (sc-152), 
and Met (Met-C12, Sc-10) were from Santa Cruz 
Biotechnology (Santa Cruz, CA); rabbit polyclonal anti-
β-catenin (ab16051) and anti-MMP14 (ab3644) 
antibodies were purchased from Abcam Inc. (Boston, 
MA); mouse monoclonal anti-β-actin antibody was 
from Sigma-Aldrich (St. Louis, MO). The anti-perlecan 
antibody has been previously characterized (79,80).  
Slot Blot Assay for the Analysis of Secreted VEGFA 
— Cells were treated with decorin protein core in 
DMEM for 24 h. Conditioned medium was collected, 
filtered, then briefly centrifuged and applied to the slot 
blot sample acceptor. Suction was applied for 30 min to 
ensure attachment to the nitrocellulose membrane, 
which was washed, and blocked overnight. Incubation 
with a primary antibody specific for the secreted factor 
was followed by application of an infrared-labeled 
secondary antibody and subsequent visualization and 
quantification via the Odyssey Infrared System.  
Transient Knockdown of Met Receptor—Transient 
knockdown of the Met receptor was achieved via 
utilization of a cocktail consisting of three validated 
siRNAs specific for Met mRNA (Met siRNA sc-29397 
Santa Cruz). Briefly, six-well plates were seeded with 
2x105 HeLa cells, followed by incubation overnight at 
37°C until cultures were 70% confluent. Targeting 
siRNA duplex at a final concentration of 80 pM was 
added to diluted Lipofectamine 2000 (Invitrogen, Grand 
Island, NY) in OPTI-MEM I Reduced Serum Medium 
(GIBCO, Carlsbad, CA). Transfection was carried out 
for 48 h at 37°C and the cells were then treated with 
DMEM or decorin (500 nM) for an additional 24 h. 
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Verification of siRNA-mediated knockdown of the Met 
receptor was determined via immunoblotting using Met 
specific antibodies.  
Quantitative Real Time PCR Analysis—Gene 
expression analysis by quantitative real-time 
polymerase chain reaction (qPCR) was carried out as 
described before (81) with minor modifications. Briefly, 
sub-confluent (~1.5 x106 cells) 3.5 cm2 dishes of HeLa 
cells were treated for 24 h with either PBS (mock) or 
500 nM decorin protein core in DMEM. After 
incubation, cells were lysed directly in 500 μl of TRIzol 
Reagent (Invitrogen). Tumor RNA was obtained as 
described before (52).  Subsequent isolation of RNA 
and cDNA synthesis proceeded as for cell culture. As 
such, total RNA (1 μg) was annealed with Oligo (dT) 
primers and cDNA was synthesized utilizing the 
SuperScript Reverse Transcriptase II (Invitrogen) 
according to the manufacturer’s instructions.  Gene 
specific primers were verified before use (supplemental 
Table 1). The target genes and endogenous 
housekeeping gene (ACTB) amplicons were amplified 
in independent reactions using the Brilliant SYBR 
Green Master Mix II (Agilent Technologies, Cedar 
Creek, TX).  All samples were run in quadruplicate on 
an Mx3005P Real Time PCR platform (Agilent) or on a 
LightCycle 480-II (Roche, Basel, Switzerland) and the 
cycle number (Ct) was obtained for each independent 
reaction. Fold change determinations were made 
utilizing the Comparative Ct method for gene 
expression analysis. Briefly, Delta Ct (ΔCt) values are 
representative of the normalized gene expression levels 
with respect to ACTB (β-actin as the endogenous 
housekeeping control). Delta Delta Ct (ΔΔCt) values 
represent the experimental cDNA (samples treated with 
500 nM decorin protein core) minus the corresponding 
gene levels of the calibrator sample (samples treated 
with PBS mock). Finally, the reported fold change 
represents an average of the fold changes as calculated 
using the double ΔCt method (2-ΔΔCT). Data derive from 
two-three independent trials for each gene of interest. 
RT2 Profiler PCR Array—The specific expression of 
angiogenic genes was evaluated using a human RT2 
ProfilerTM PCR Array (SABiosciences) which 
contained primers for the detection of 84-different 
known angiogenic genes. This analysis was carried out 
according to the manufacturer’s instructions. Briefly, 
sub-confluent 3.5 cm2 dishes of HeLa cells were treated 
for 24 h with either PBS (vehicle) or 500 nM decorin 
protein core in DMEM. After incubation, the cells were 
lysed directly in TRIzol Reagent (Invitrogen) for 
subsequent RNA isolation. Total RNA was reverse 
transcribed to cDNA using the RT2 First Stand Kit 
(SABiosciences) followed by combination with the RT2 
qPCR Mastermix. This volume was evenly distributed 
among two PCR Array plates. Consecutive rounds of 
qPCR were performed under normal thermal conditions 
followed by data analysis according to the above 
mentioned Comparative Ct method post normalization 
to five independent controls.  
Immunofluorescence—Immunofluorescent studies 
was performed as described before (53,82,83). 
Approximately 5 x 104 HeLa cells were plated on 4-
well chamber slides (BD Biosciences) and grown to full 
confluence in 10% FBS at 37 ºC. Cells were switched to 
DMEM/2% FBS 2 h prior to each treatment. Slides 
were rinsed twice with DPBS and fixed/permeabilized 
with ice-cold methanol for 10 min. Subsequently slides 
were subjected to standard immunofluorescence 
protocols, and mounted with Vectashield (Vector 
Laboratories Inc, Burlingame, CA). Following 
incubation with various primary antibodies, detection 
was determined using goat anti-mouse IgG Alexa 
Fluor© 488 and goat anti-rabbit IgG Alexa Fluor© 594 
(Invitrogen). Images were acquired using a Leica 
DM5500B microscope with Advanced Fluorescence 1.8 
software (Leica Microsystems, Inc). All the images 
were analyzed with Adobe Photoshop CS3 (Adobe 
Systems, San Jose, CA). Fluorescence quantification 
was done with ImageJ software.  
Gelatinase Zymography—Gelatinase activities were 
evaluated in tumor conditioned media (10 μl) collected 
from HeLa cells after incubation with 500 nM decorin 
for a period of 24 h were quantified with 10% SDS-
PAGE incorporating denatured rat tail type I collagen 
(Sigma) (84). The sample buffer did not contain 
reducing agents. Gels were washed in 2.5% v/v Triton 
X-100 (1 h at room temperature) and incubated 
overnight in 50 mM Tris HCl, pH 7.6, 0.1 mM NaCl, 10 
mM CaCl2,, 0.05% Brij in the presence or absence of 20 
mM EDTA (all from Sigma). Enzymatic activity was 
visualized as negative staining with Coomassie Brilliant 
Blue R-250 (Sigma) and quantified using Quantity One 
1-D Analysis Software (Bio-Rad). The results of six 
samples per group were averaged.  
Quantification of MMP Levels—The detection of 
total MMP-9 and MMP-2 present in tumor-conditioned 
medium was carried out by ELISA according to the 
individual kits assaying Human MMP-9 and Human 
MMP-2 Immunossay Quantikine Colorimetric 
Sandwich ELISA (R&D Systems, Minneapolis, MN) 
according to the manufacturer’s protocol. These assays 
employ a quantitative sandwich ELISA technique via a 
monoclonal antibody specific for both the 92-kDa Pro-
MMP9 (gelatinase B) as well as the 82-kDa-active 
MMP9. Detection of human MMP-2 (gelatinase A) via 
Human MMP-2 Quantikine kit was performed with a 
polyclonal antibody cognant for the 72-kDa MMP2.  
Briefly, tumor conditioned medium samples generated 
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by a sub-confluent six-well plate of HeLa cells, 
previously treated with either PBS (mock control) or 
decorin protein core (500 nM) for 24 h, were collected. 
The pre-coated plates received Assay Diluent followed 
by application of standard, control, and sample cell 
media aliquots followed by 2h incubation at 25 oC.  The 
plates were washed extensively, incubated with the 
substrate for 30 min and read at 450 nm.  
Evaluation of mRNA Stability—Determination of 
mRNA decay processes were evaluated in HeLa via 
pre-treatment of Actinomycin D (Sigma, St. Louis, 
MO) for 1 h followed by treatment (4 h) with decorin 
core protein (100, 500 nM). At the conclusion of the 
experiment, media was aspirated, cells were washed in 
PBS and lysed in TRIzol for RNA isolation and cDNA 
synthesis (see above protocol). Yielded cDNA was 
subsequently analyzed via qPCR (see above protocol 
for workflow and ΔΔCt methodology) to evaluate the 
resulting non-steady state mRNA levels of selected 
target genes in the presence or absence of decorin. 
MMP-9 Functional Assay—Evaluation of  
endogenous MMP-9 activity present in HeLa 
conditioned media in the absence or presence of decorin 
core protein (500 nM) was carried out via utilization of 
the SensoLyte® Plus 520 MMP-9 Assay Kit  (AnaSpec, 
San Jose, CA) (85,86).  Briefly, following the 24 h 
incubation with decorin, tumor conditioned DMEM was 
collected, filtered (0.2 μm), and centrifuged. The 
supernatant was subsequently used to generate two-fold 
dilutions (up to and including 1:128). About 100 μl of 
each dilution was added to each microplate well, which 
contained a pre-coated monoclonal anti-human MMP9 
antibody. Pulldown (1 h at 25 oC) of endogenous 
MMP9 was succeeded by activation of the pro-MMP9 
present only in the standard curve with 1 mM p-
aminophenylmercuric acetate (APMA) for 2 h at 37 °C 
but not for the control or experimental samples. This 
allowed direct evaluation of endogenous active MMP9 
in the applied samples. Next, active MMP9 activity was 
assayed via the addition of the synthetic MMP9 5-
FAM/QXL520 FRET peptide. Following an 8-h 
incubation with this MMP9 substrate, end point analysis 
was determined by measuring the fluorescence 
intensity, which measures the activity of MMP9, on a 
BioTek Synergy 4 plate reader (BioTek Instruments, 
Winooski, VT) at an Em/Ex of 490/520 nm.  
Tumor Xenograft Matrigel Plug Assays—
Approximately 80 μl of MatrigelTM (BD Biosciences, 
Bedford, MA) containing ~106 MDA-231(GFP+) cells 
and HGF (10 ng/ml), in the presence or absence of 
decorin (200 nM) were injected into 4 dorsal 
subcutaneous regions of 6 severe combined 
immunodeficient (SCID), nude, female mice (Charles 
River Lab., Malvern, PA). Mice were sacrificed 14 days 
post injection and their skins were removed, fixed in 
10% buffered formalin (Fisher Science, Fair Lawn, NJ), 
and then photographed from the inside to analyze the 
resulting angiogenic reaction.  Quantification was 
achieved by ImageJ software and superimposing grids 
onto each photographed skin with each box of the grid 
representing 1 mm2. Fifty, randomly-selected boxes 
around each Matrigel plug were analyzed by 
morphometry. That is, the number of times a blood 
vessel intersected each box was recorded for both 
“Matrigel+HGF” and “Matrigel+HGF+decorin”. Values 
were converted into µm2 and a Student’s two-sided t 
test (see below) was used to compare the values 
obtained from the control and experimental conditions. 
Tumor Xenografts—All animal studies were 
approved by the Institutional Review Board of Thomas 
Jefferson University. For orthotopic mammary tumor 
xenografts, SCID female mice (Charles River Lab., 
Malvern, PA) were injected in the upper left mammary 
glad with 1-2 x 106 MDA-231(GFP+) cells. The mice 
were randomized once tumors were established. Half 
the mice received a dose of 5 mg/kg decorin protein 
core injected intraperitoneally every 2 days. The 
controls received 100 μl PBS. On day 24, the majority 
of animals were sacrificed and all major organs and 
tumors were dissected and frozen subsequent to analysis 
via immunofluorescence or qPCR. HeLa xenografts 
were generated as described before (52).  
Dot Blot Analyses of Secreted Factors—Evaluation 
of secreted factors was done, in part, via dot blot 
analysis. HeLa and MDA-231 cells were treated as 
described under serum free conditions (see below). 
Tumor cell conditioned medium was collected, filtered, 
briefly centrifuged and applied to the dot blot (Minifold 
I, Schleicher and Schuell, Keene NH) sample well plate. 
Constant vacuum (~80 mbar) was applied for 30 min to 
ensure attachment to the nitrocellulose membrane. 
Membrane was washed, and blocked overnight in 5% 
BSA. Incubation with primary antibody specific for the 
secreted factor was followed by application of an HRP-
conjugated secondary antibody and subsequent 
visualization with ECL technique. Densitometry was 
performed with ImageJ software.   
Quantification and Statistical Analysis—
Immunoblots were quantified by scanning densitometry 
using ImageJ software or using the Odyssey software 
for the infrared-labeled secondary antibodies. All the 
experiments were carried out in triplicate and repeated 
at least three times. Results are expressed as mean 
±SEM. Statistical analysis was performed with 
SigmaStat for Windows version 3.10 (Systat Software, 
Inc., Port Richmond, CA). Significance of differences 
was determined by unpaired Student’s t test. Statistical 
significance was achieved with p<0.05. For 
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quantification of immunofluorescence studies, 
fluorescence intensity and 3D surface plots were 
quantified by measuring pixels with ImageJ software as 
described before (52).  
 
RESULTS  
Decorin Broadly Impedes the Transcription of Pro-
Angiogenic Genes and Upregulates the Expression of 
Angiostatic Genes—First, we determined the effects of 
decorin on the expression of angiogenic genes using a 
human RT2 ProfilerTM PCR Array (SABiosciences). 
This PCR array platform profiles the expression of 84 
key genes involved in modulating the biological 
processes of angiogenesis, including growth factors and 
their receptors, chemokines and cytokines, matrix and 
adhesion molecules, proteases, as well as transcription 
factors.  
To this end, HeLa cells were treated for 24 h in the 
absence or presence of 500 nM decorin protein core 
under normoxic conditions whereupon total RNA was 
harvested, reverse transcribed to cDNA libraries and 
then applied to the cognate PCR Array plates. 
Normalization of raw Ct values to five endogenous 
controls allowed for a comparative ΔΔCt analytic 
approach between calibrator samples (PBS control) and 
experimental (decorin) samples. First, only ~10% of all 
genes were changed: two were upregulated and six were 
down-regulated by decorin (Fig. 1A). Notably, TIMP3 
was induced over 4 folds by decorin and this product 
has been previously shown to be antiangiogenic (87). 
The six down-regulated genes, (Fig 1A) including 
hypoxia inducible factor-1α (HIF1A), sphingosine 1-
phosphate receptor 1 (S1PR1), endoglin (ENG), 
fibroblast growth factor 2 (FGF2), and integrin αV 
(ITGAV), all were quite interesting because all have 
been implicated in promoting key aspects of angiogenic 
signaling (88-94), with the notable exception of 
thrombospondin-1 (THBS1) which has been shown to 
exhibit potent anti-angiogenic activities (95,96).  
Next, we validated the modulated genes using qPCR 
(Fig. 1B). The great majority of the transcriptional 
changes reported by the PCR Array were reliably 
reproduced. However, the expression changes for 
aminopeptidase-N (ANPEP or CD13) and S1PR1 could 
not be reproduced and validated most likely reflecting 
either an exceedingly low transcript copy number or 
sheer lack of expression in HeLa cells. Notably, 
thrombospondin-1, a well-known anti-angiogenic factor 
(95,96) was found to be slightly downregulated in the 
presence of decorin (Fig. 1A). However, verification of 
this gene via qPCR revealed THBS1 to be significantly 
upregulated by ~ 2.5 folds (p<0.001, Fig. 1B). 
Additional pro-angiogenic gene targets found to be 
repressed by decorin included VEGFA and Met. Since 
we normalized Ct values to endogenous ACTB in each 
sample, we conducted qPCR to ensure the expression of 
this housekeeping gene was not affected by exogenous 
decorin. Thus, after 24 h we found that ACTB 
(supplemental Fig. S1A) in HeLa was not significantly 
modulated by decorin (500 nM). Further, we sought to 
determine ACTB over time and demonstrate that up to 8 
h in HeLa, ACTB mRNA levels also did not 
significantly change (supplemental Fig. S1B). 
Therefore, we conclude the changes seen in target gene 
expression are not a result of β-actin modulation at the 
mRNA level. 
The expression changes were done at steady state 
kinetics but could alternatively represent the effects of 
decorin on modulating mRNA stability and/or 
accelerating decay processes of the target message. To 
address this possibility, we evaluated VEGFA, HIF1A, 
and THBS1 in the presence of decorin following pre-
treatment with Actinomycin-D in HeLa. We found no 
further changes in mRNA for VEGFA (supplemental 
Fig. S1C), HIF1A (supplemental Fig. S1D) or THBS1 
(supplemental Fig. S1E), indicating that decorin does 
not modulate mRNA levels post-transcriptionally by 
promoting mRNA decay. We can thus conclude that the 
changes seen at the steady state reflect a decrease at the 
level of transcription. 
Collectively, these expression data implicate decorin 
as a broad suppressor of the tumor angiogenic response 
by exhibiting a unique duality. It effectively represses 
pro-angiogenic gene targets under normoxia and 
simultaneously promotes the expression of various anti-
angiogenic effector molecules. 
Exogenous Decorin Potently Attenuates VEGFA 
Signaling Components—Among the downregulated 
genes reported in the expression analysis above, we 
chose to focus on the VEGFA signaling axis as it relates 
to tumor angiogenesis. First, we determined whether the 
activity of decorin could be generalized to normal as 
well as transformed cells. Thus, we tested two tumor 
cell lines and normal endothelial cells for the effects of 
exogenous decorin on VEGFA production. Following 
decorin exposure, we found a uniform reduction of 
secreted VEGFA in the media conditioned for 24 h by 
HeLa (cervical carcinoma) and MDA-231 (triple-
negative breast carcinoma) cells as well as from 
HUVECs (p <0.001, Fig. 2 A,B).   
The reduced levels of VEGFA found in the 
conditioned medium could be a consequence of a 
corresponding decrease in total cellular stores of 
VEGFA or an inhibitory effect of VEGFA secretion. To 
differentiate among these possibilities, we probed the 
cell lysates using immunoblotting with the same anti-
VEGFA antibody. We found a decrease in cellular 
VEGFA in both HeLa and MDA-231 and to a lesser 
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extent in HUVECs (p<0.001 and p<0.01, respectively, 
Fig. 2C, D). The difference in sensitivities among these 
cell lines are attributable to higher Met in HeLa and 
MDA-231 (6- and 8-folds higher, respectively) relative 
to HUVEC (data not shown). Enhanced expression of 
this high-affinity receptor would further sensitize the 
cells to the angiostatic properties of decorin.  
Next, we found a significant reduction of both 
secreted and cellular VEGFA (supplemental Fig. 
S2A,B) after 24h in HeLa and MDA-231 following 
decorin treatment (100 nM). Thus, a concentration of 
100 nM is sufficient to evoke reduction of secreted and 
cellular VEGFA. 
Time course experiments utilizing HeLa cell lysates 
treated with a constant concentration of decorin 
revealed a progressive decrease of both secreted (Fig. 
2E,F) and cellular VEGFA (supplemental Fig. S2C) 
relative to mock (PBS) treated controls for up to 12 h. 
Downregulation of secreted and cellular VEGFA was 
noted as early as 2 h (cfr. Fig. 2F and S2C); thus, we 
conducted a VEGFA time course and found a gradual 
reduction of VEGFA mRNA persisting for up to 8 h in 
HeLa (supplemental Fig. S2D). Furthermore, 
immunofluorescent analysis confirmed reduction of 
cellular VEGFA in HeLa cells following decorin 
treatment (supplemental Fig. S2E ). 
Interestingly, cellular VEGFA levels maintained a 
stable decrease starting at 8 h and lasting for up to 24 h, 
which mirrored VEGFA expression. However, secreted 
VEGFA seemed to have a sharper decrease at later time 
points, potentially implicating an attenuation of the 
secretory pathway. 
Collectively, our findings indicate that decorin 
affects VEGFA production in both transformed and 
normal cells and further corroborate the marked 
transcriptional inhibition obtained under normal oxygen 
tension. Moreover, these data postulate a firm role for 
decorin as a negative regulator of VEGFA by inhibiting 
its expression at multiple levels of control. 
Decorin Suppresses VEGFA in the Presence of 
Constitutively-active HIF-1α under Normoxic 
Conditions—Further interrogation behind the 
mechanism of decorin-mediated suppression of VEGFA 
signaling led us to evaluate the role of HIF-1α based on 
the potent inhibition of HIF1A  transcription under 
normoxic conditions (cfr. Fig. 1). The HIF1A gene 
encodes a key basic-helix-loop-helix transcription factor 
that dimerizes with the constitutively expressed HIF-
1β/ARNT subunit to form a stable complex capable of 
recruiting transcriptional co-activators such as 
CBP/p300 to proximal promoters (97). Consequently, 
the genetic subsets targeted by HIF-1α are primarily 
responsible for orchestrating and executing the cellular 
hypoxic response that will drive angiogenesis. It is well 
established that VEGFA expression is transcriptionally 
driven by HIF-1α (89,98).  
Utilization of specific MDA-231(GFP+) cell lines, 
which overexpress either wild-type HIF-1α (MDA-231 
wtHIF-1α) or a mutated HIF-1α (MDA-231 mutHIF-
1α) allowed for direct evaluation of HIF-1 α function in 
normoxia. In the HIF-1α mutant, the proline residues 
residing within the oxygen-dependent degradation 
domain have been mutated to alanine (P402A and 
P564A) that culminate in a constitutively-active HIF-
1α. This form is no longer a proper substrate for PHD2-
mediated hydroxylation and subsequent protein Von 
Hippel-Lindau (pVHL)-dependent ubquitination leading 
to proteasomal degradation. Thus, activated HIF-1α is 
stable under normoxic conditions (78). We discovered 
that decorin evoked downregulation of both wild-type 
and mutant HIF-1α (Fig. 3A,B). Immunofluorescence 
detection of both HIF-1α and VEGFA showed a 
significant decrease in both wild-type and mutant cells 
(Fig. 3C,D). We found that secreted VEGFA was also 
reduced in the two cell types (Fig. 3E), further 
supporting the data presented above. Thus, decorin 
evokes downregulation of HIF-1α protein in mammary 
carcinoma cells harboring either wild-type or a 
constitutively-active HIF-1α.  
Consistent with this notion, pVHL, the E3-ubquitin 
ligase complex liable for degrading HIF-1α under 
normoxic conditions (99) was upregulated nearly two 
folds in MDA-231wtHIF-1α, but was unchanged in 
MDA-231mutHIF-1α (supplemental Fig. S3A) 
following increasing concentrations of decorin. Further 
evaluation of pVHL in parental MDA-231 cells 
demonstrated a modest induction (supplemental Fig. 
S3B); however, this was in contrast to the nearly 40% 
inhibition of HIF-1α protein after 4 h (supplemental 
Fig. S3B), which is consistent with the above findings. 
Of note, treatment of HeLa demonstrated a similar trend 
of modestly induced pVHL correlating with reduced 
HIF-1α (not shown).  
Collectively, these data posit a potential role of 
pVHL, in conjunction with the already declining HIF1A 
expression levels, for the early stages of HIF-1α 
antagonism. Therefore, inhibition of HIF-1α does not 
seem to rely as heavily on pVHL, instead decorin 
evokes a prominent transcriptional repression. This 
provides a novel role of attenuating traditional HIF-
1α/VEGFA signaling under normoxic conditions to 
curb tumor growth. 
Decorin Disables an Array of Activating 
Transcription Factors Essential for the Proper 
Expression of HIF1A and VEGFA Under Normoxia—
To further investigate the potential mechanism of 
decorin antiangiogenic activity, we performed a detailed 
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expression analysis of pertinent transcription factors 
essential for driving the expression of both HIF1A and 
VEGFA.  Multiple transcription factors are known to 
have consensus binding sites within the promoter of 
VEGFA, in particular numerous sites are present for Sp1 
and AP-1 as well as a HIF-1α response element (HRE) 
(89). Coincidentally, these factors are also essential for 
promoting and allowing HIF1A expression.  
Taking this information into account we evaluated 
FOS and SP1 expression within mutHIF-1α cells 4 h 
and 24 h post exposure to decorin. The expression of 
FOS was significantly decreased at both time points (p 
<0.001 and p<0.01, Fig 3F,G), with a greater reduction 
occurring after 4h with some recovery after 24 h. A 
similar expression signature was obtained with SP1 at 
both 4 and 24 h (p<0.001, 3F,G).  
Next, CTNNB1 (β-catenin) expression exhibited a 
reduction (p<0.001, Fig. 3F) following 4h; however, 
after 24h, CTNNB1 expression seemed to recover 
significantly (Fig. 3G), and return almost to baseline (p 
<0.05, Fig. 3G). These data are congruent with the 
finding of seven TCF/LEF binding sites embedded 
within the proximal promoter of VEGFA (100) and thus 
enforce the critical role of β-catenin signaling in the 
promotion of VEGFA-mediated tumor angiogenesis. 
Further, the expression of HIF1A decreased 
significantly at 4h (p<0.01, 3F) and this was protracted 
for up to 24 h (p<0.001, 3G). Finally, in regard to 
VEGFA expression, both time points revealed a potent 
suppression in MDA-231 mutHIF-1α cells (p<0.001, 
Fig. 3F,G). Overall, these expression data corroborate 
the above-mentioned protein and immunofluorescence 
data. 
In summary, these data argue for a role of decorin in 
promoting a cessation of pro-angiogenic transcription 
via a potent reduction in multiple genes necessary for 
the expression of HIF1A and VEGFA. More importantly 
is the ability of decorin to achieve potent angiostasis in 
an activated HIF-1α cell line under normoxic 
conditions. Further, classical Ras/MAPK signaling 
cascades emanating from RTKs such as Met (see 
below), are known to target and phosphorylate Sp1 via 
the p42/p44 MAPK, resulting in full activation and 
specific targeting of Sp1 to the proximal promoter of 
VEGFA for competent transactivation (101).  
The role of Met in Regulating Angiogenesis vis-à-vis 
VEGFA Signaling—We have previously shown that 
binding of decorin to Met is oppositional and 
subsequent receptor internalization and degradation 
ensues (52). Therefore, focusing on the prevalent 
association of Met in the process of tumor angiogenesis 
and the documented interaction with decorin, we 
determined the link of Met in the process of decorin-
mediated angiostasis. This link was established via the 
transfection of a cocktail of three validated siRNAs 
targeting Met mRNA. We reasoned that Met 
downregulation at the mRNA level would mimic the 
proteasomal-induced degradation of Met evoked by 
exogenous decorin.   
The siRNA targeting Met reduced the receptor to 
barely detectable levels without affecting β-actin levels 
(Fig. 4A). Importantly, knockdown of Met recapitulated 
the downregulation of cellular VEGFA (Fig. 4B). 
Furthermore, dual treatment of HeLa cells with both 
targeting siRNA followed by a 24 h incubation with 
decorin did not result in additional inhibition of cellular 
VEGFA, in agreement with Met acting as the main 
signaling receptor for decorin-evoked inhibition of 
VEGFA (Fig. 4B).  
As discussed above, decorin suppresses the 
transcription of targets critical for the promotion of 
angiogenesis. Therefore, to dissect if decorin is 
transducing these anti-angiogenic effects via Met, we 
used siRNA targeting Met. This strategy achieved Met 
transcript reduction by ~50% (Fig. 4C), relative to the 
scrambled siRNA control.  Interestingly, depletion of 
Met alone induced transcriptional changes in VEGFA 
and CTNNB1 analogous to decorin-treated HeLa cells 
(Fig. 4C,E), but to a lesser degree. Finally, MYC a 
downstream target of the Met/β-catenin antagonism 
(52), was found to change only modestly (Fig. 4C). 
Surprisingly, HIF1A expression was not appreciably 
affected under these conditions (Fig. 4C). Several 
reasons could account for this discrepancy such as the 
requirement of decorin to evoke changes in HIF1A 
expression vis-à-vis Met engagement, compensatory 
mechanisms mediated via HIF-2α, or because signaling 
is being integrated by decorin over multiple RTKs, such 
as the EGFR.  
As a primary downstream effector of Met (52), β-
catenin was prominently reduced via decorin (Fig. 4 D). 
This inhibition also extended to CTNNB1 transcripts 
(Fig. 4E), to an extent comparable to MDA-231 wtHIF-
1α as shown previously (cfr. Fig. 3F). As decorin 
downregulates Met protein levels via cavaeolar-
mediated endocytosis and proteasomal-dependent 
degradation (47), we tested the effects of decorin on 
MET transcript levels. Notably, we found a significant 
reduction in the expression of MET (cfr. Fig. 1B) 
indicating disruption of a positive feedback loop that 
exists between Met and β-catenin upon decorin 
engagement (102). It is tempting to speculate that 
decorin is abrogating both β-catenin and Sp1 signaling 
subsequent to Met degradation, resulting in 
transcriptional inhibition of the VEGFA locus. 
Importantly, this fosters a scenario wherein a growth 
factor receptor dependent mechanism of HIF-1α 
regulation is feasible, and is congruent with the 
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biological activity decorin exerts on Met (103). 
Notably, decorin-null mice have increased expression of 
β-catenin in the enteric epithelium (57). 
Further proof-of-principle of decorin mediated 
angiostasis was established by employing a tumor 
xenograft mouse Matrigel assay. To this end, we 
injected ~106 MDA-231 (GFP+) cells mixed with ~80 
μl of Matrigel and 10 ng/ml HGF in the absence or 
presence of decorin (200 nM) into four dorsal 
subcutaneous regions of SCID mice. After 14 days with 
HGF, a strong angiogenic reaction was achieved 
surrounding the tumors (asterisk, Fig. 4F, left panel). 
This is in stark contrast to the combined treatment of 
decorin and HGF for the same time period (asterisk, 
Fig. 4F, right panel). Morphometric analysis of the 
vessel density revealed a marked suppression of 
vascularity associated with the decorin-containining 
xenografts (p<0.001, Fig. 4G). 
These in vivo findings argue a very strong case for 
the ability of decorin to retard tumor angiogenesis in 
MDA-231 tumor xenograft Matrigel assays. These data 
establish and enforce a role of Met as being involved in 
a non-canonical Wnt/β-catenin signaling pathway 
induced by HGF to promote tumor angiogenesis vis-à-
vis VEGFA, which can be abrogated by decorin. 
Decorin Inhibits the Induction and Activity of Matrix 
Metalloproteinases—Aggressive neoplasms often show 
increased expression of a class of zinc-dependent 
gelatinases known as matrix metalloproteases (MMPs)   
capable of degrading the matrix as well as liberating a 
host of pro-angiogenic factors (104,105). Primarily 
pertinent for the current study is the ability of matrix-
bound VEGFA to be released, making the factor readily 
available for use by the surrounding angiogenic cells 
(106). Taking this into account, we analyzed the 
expression and activity of MMP9 and MMP2, both of 
which are under the control of β-catenin signaling 
(107). MMPs are secreted by the host cell as a zymogen 
(otherwise known as the “proform”), followed by a 
proteolytic cleavage event to yield the catalytically 
active enzyme. Thus, to assess the activity of secreted 
MMPs, media conditioned for 24 h by HeLa cells in the 
absence or presence of exogenous decorin (500 nM) 
were subjected to gelatin zymography. This functional 
assay revealed a dramatic reduction in the activity of 
MMP9 as well as a more modest, but still significant, 
decrease in the activity of MMP2 (Fig. 5A) relative to 
control conditioned media (p<0.001 and p<0.05, 
respectively, Fig 5B). In agreement with gel 
zymography, utilization of a MMP9 fluorescence 
resonance energy transfer (FRET) probe assay revealed 
>50% reduction in the activity of endogenous MMP9 
present in HeLa conditioned media following decorin 
treatment (Fig. 5C). In support of these functional data, 
gene expression analysis revealed an effective decrease 
in MMP9 (p<0.001, Fig. 5D) and a modest but 
statistically significant reduction in MMP2 (p<0.05, 
Fig. 5D). We then performed ELISA with antibodies 
specific for both MMPs and showed a significant 
decrease in secreted MMP9 (p<0.001, Fig. 5E) without 
any significant reduction in secreted MMP2 (Fig. 5F). 
These data are uniformly consistent with the gelatin 
zymography and gene expression data presented above. 
Next, we evaluated the role of a membrane type 
MMP, known as MT1-MMP (or MMP14) which pro-
angiogenic and pro-invasive via the cleavage and 
activation of MMP2 and MMP9 (108,109). To this end, 
we carried out immunoblotting to detect MT1-MMP in 
our HeLa samples and subsequently found no 
significant change in MT1-MMP levels (Fig. 5G). We 
also found no appreciable changes in the expression of 
MMP14 (not shown).  
Collectively, these data indicate that decorin is most 
likely not attenuating MMP2/9 activity or expression 
via modulation of a presumed upstream activator, i.e. 
MT1-MMP. Moreover, these data provide further 
evidence for the potent transcriptional control decorin 
exerts over these loci by abrogating non-canonical β-
catenin signaling.  
Finally we evaluated the role of TIMP3, a secreted 
protein that binds tightly to the extracellular matrix and 
is also a direct inhibitor of ADAM-17/TACE (110). 
TIMP3 has also been proposed to be a tumor suppressor 
in several human cancers such as kidney, colon, brain, 
memingomas, and non-small cell lung cancers (111-
113). Interestingly, TIMP3 has also been reported to 
reduce Met receptor shedding (114). According to the 
array (cfr. Fig. 1), decorin induces TIMP3 expression; 
thus, we evaluated HeLa cell conditioned media and 
found an almost 5-fold increase in secreted TIMP3 
(supplemental Fig. S4A). Further, immunofluorescent 
analysis of MDA-231(GFP+) tumor xenograft 
cyrosections also revealed an abundant increase in 
TIMP3 signal intensity (supplemental Fig. S4B), thus 
indicating a decorin-dependent induction of TIMP3 in 
vitro and in vivo. 
We conclude that decorin suppresses the expression 
and functional activity of MMP2/9 at least in part by 
antagonizing Met signaling. This would result in a 
protracted degradation and inhibition of β-catenin in a 
non-canonical Wnt, RTK-dependent manner insofar as 
both MMP2 and MMP9 are direct transcriptional targets 
of β-catenin (107).  
Decorin Induces Thrombospondin-1 both in Cell 
Cultures and Tumor Xenografts—Next, we determined 
the levels of secreted thrombospondin-1 in media 
conditioned by HeLa cells that were exposed to either 
vehicle (control) or decorin (500 nM) for 24 h. Using 
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quantitative dot blot analysis, we found a marked 
increase in the secretion of thrombospondin-1 (Fig. 6A) 
whereas the secretion of perlecan (internal control) was 
not appreciably changed (Fig. 6B).  Similarly, the 
cellular levels of thrombospondin-1 were also 
significantly increased by decorin (Fig. 6C).  
Next, we utilized mice bearing HeLa tumor 
xenografts which were treated with intraperitoneal 
injections of decorin (5 mg/Kg) every other day over a 
period of 23 days. At the end of the treatment, the 
volume of the decorin-treated tumors was ~half the size 
of vehicle-treated counterparts (p<0.001, n=6 per group, 
Fig. 6D).  Immunofluorescence analysis of frozen tumor 
sections showed a marked induction of endogenous 
human thrombospondin-1 in the treated tumor 
xenografts (Fig. 6E). Concurrently, the amount of 
endogenous VEGFA was markedly reduced in the 
decorin-treated xenografts (supplemental Fig. S5). 
Further in vivo relevance of decorin-mediated 
angiostasis was determined via qPCR to evaluate the 
expression of pro-angiogenic markers present in the 
tumor xenografts. In the treated xenografts, there was a 
substantial downregulation of MMP2, MMP9 and 
VEGFA (p<0.001, Fig. 6F) and a marked upregulation 
(up to 15 folds) of THBS1 (p<0.001, Fig. 6G) 
transcription.   
Overall, these data correlate well with the in vitro 
findings and further strengthen the concept and current 
rationale while providing a proof-of-principle for 
decorin-mediated inhibition of VEGFA-mediated tumor 
angiogenesis.  
Systemic Administration of Decorin Inhibits Pro-
angiogenic Markers in Orthotopic Tumor Xenografts —
To further strengthen the in vivo relevance of our data, 
we generated orthotopic mammary tumor xenografts 
using triple-negative breast carcinoma cells MDA-
231(GFP+). In this case, systemic treatment with 
decorin protein core resulted in a marked induction of 
endogenous human thrombospondin-1 by systemic 
delivery of decorin (supplemental Fig. S6A). In 
addition, the HeLa xenografts demonstrated an almost 
complete loss of cellular VEGFA within the decorin 
treated cohort relative to control animals when analyzed 
via immunofluorescence and quantified as 3D surface 
plots of the fluorescent signal (supplemental Fig. S6B). 
Collectively, our results indicate that decorin can 
simultaneously downregulate proangiogenic factors and 
upregulate antiangiogenic factors in two animal models 
of tumorigenesis.  
 
DISCUSSION 
The steps involved in tumor progression have been 
derived from multiple animal models and reflect 
discrete changes within the genome via activation of 
oncogenes or the silencing of tumor suppressor genes 
that drive a normal cell through transformation to a 
malignant phenotype (115). A key milestone on the path 
to cancer progression is the development of a competent 
tumor vasculature to provide a blood supply as well as a 
conduit for metastasis.  This event is mediated via a 
discrete step known as the angiogenic switch, which 
results in an imbalance of key pro-angiogenic cytokines 
and angiogenic inhibitors. Previous reports implicate 
decorin as a powerful inhibitor of tumor angiogenesis 
(73). In our current working model (Fig. 7) stromal 
decorin engages and abrogates the HGF/Met signaling 
axis, acting as a potent suppressor of VEGFA-mediated 
tumor angiogenesis. Decorin binding to Met initiates 
receptor internalization via increased phosphorylation 
of Tyr1003, which is a recruitment site for the E3 
ubquitin ligase c-Cbl. This mechanism triggers 
caveolar-mediated endocytosis of the receptor complex, 
culminating in the transcriptional repression of HIF-1α, 
β-catenin, MYC, and SP1 under normoxic conditions, 
coincident with decreased protein levels and 
proteasomal degradation of HIF-1α, β-catenin, and 
MYC (Fig. 7). The combinatorial effect of inhibiting 
this constellation of transcription factors results in the 
impairment of VEGFA, MMP2, and MMP9 expression, 
and a simultaneous transcriptional induction of THBS1 
and  TIMP3, potent inhibitors of angiogenesis and the 
MMP family. Moreover, we envisage that a concurrent 
reduction of MMP2/9 activity coupled with induction of 
thrombospondin-1 and TIMP3 allows for potent 
angiostasis in the matrix, acting to further restrict 
matrix-bound VEGFA from engaging cognate receptors 
(e.g. VEGF-R2) on the surface of tumor endothelial 
cells (Fig. 7). The potential involvement of MT1-MMP 
(MMP14) was evaluated and found to be unchanged 
since this membrane type MMP is postulated to 
orchestrate several steps directly during cancer 
progression including the degradation of physical 
barriers (e.g. laminin-5) necessary for cancer cell 
invasion (invadopodia), migration, activation of TGF-β, 
and indirectly for tumor angiogenesis through cleavage 
and activation of pro-angiogenic MMP2 and MMP9, at 
the cell surface. MT1-MMP has also been reported to 
remodel the basement membrane and regulate cell 
proliferation during renal development (116).  
Notably, thrombospondin-1 expression is negatively 
regulated by Myc (117,118), thereby allowing 
establishment of the angiogenic switch and tumor 
progression, particularly of mammary epithelial cells 
(119). Thus, an additional way through which decorin 
could induce thrombospondin-1 would be via repression 
of Myc (52). Moreover, HGF induces a severe 
repression of THBS1 expression via activation of Met 
(77). Thus, interference of the HGF/Met signaling axis, 
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as coordinated by decorin, not only serves to repress 
VEGFA but also acts to potently induce 
thrombospondin-1, further preventing Met and VEGFA 
mediated tumor angiogenesis. 
We previously reported that stable expression of 
decorin in several malignant cell lines led to inhibition 
of endogenous VEGFA expression (73). However, the 
mechanism of this effect was not investigated. In the 
present study we have expanded these original 
observations and unmasked a mechanism that is 
controlled by a decorin-evoked downregulation of Met, 
and perhaps other RTKs. An additional novelty of this 
current study lies in the identification of a normoxic and 
HIF-1α-dependent mechanism as a molecular basis for 
these findings. Furthermore, at the time of publication 
of our previous study, we were unaware of the recently-
established high affinity interaction of decorin with the 
pro-angiogenic Met receptor (51). Abrogating the 
EGFR activity by functionally blocking the receptor 
with mAb425 or utilizing AG1478, in the presence of 
decorin was able to evoke rapid activation of Met 
followed by internalization and downregulation of total 
Met levels, implicating Met as the primary receptor for 
decorin. Finally, it was subsequently found that Met has 
a substantially higher affinity for decorin relative to that 
of EGFR (51).   
This angiostatic effect has probable implications that 
attenuate the initial stages of tumor angiogenesis. In this 
phase, which precedes the activation of the angiogenic 
switch, tumor hypoxia has not yet reached a 
biologically relevant threshold to induce tumor 
vascularization. This delineates a compelling role for 
matrix-derived residents as being essential modulators 
of early angiogenic events.  
Our data presented here seemingly contradicts with a 
previously published study (120) which reported that 
decorin is able to induce VEGF production by 
recruiting Sp1, HIF-1α, and STAT3 to the cognizant 
response elements within the promoter of VEGF . This 
study, however, was performed with murine cerebral 
endothelial cells (120). Our study, in contrast, was 
conducted in two human carcinoma cell lines. In this 
context, the molecular repertoire and genomic profile of 
malignant human cervical and breast cell lines 
compared to normal mouse cerebral endothelial cells 
make comparison difficult. Further, our data concerning 
the effect of decorin for normal human endothelial cells 
suggest an inhibitory role, which is supported by a 
recent study demonstrating decorin antagonizes 
VEGFR2 in human extravillous trophoblasts and 
interfering with migration by attenuating ERK1/2 
signaling (121). 
In conclusion, our data demonstrate a novel 
antagonistic interaction of the HGF-Met signaling axis 
leading to a marked and sustainable inhibition of 
VEGFA-mediated angiogenesis under normoxic 
conditions. Potential therapeutic induction of this 
mechanism of decorin, acting as a potent angiostatic 
agent, will attenuate critical steps in the progression of a 
malignant neoplasm and will have broad medicinal 
applications as an angiostatic modality.   
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FIGURE LEGENDS 
 
FIGURE 1. Decorin inhibits VEGFA-mediated angiogenesis by attenuating proangiogenic factors.  A, RT2 PCR 
Profiler Angiogenesis Array evaluating proangiogenic gene expression changes in HeLa cells following exposure to 
500 nM decorin after 24 h. B, PCR array target gene verification performed via quantitative Real Time PCR 
(qPCR) under the same conditions as in A. PCR Profiler Angiogenesis Array and all subsequent qPCR verification 
analyses were performed in triplicate among three independent experiments, normalized to the endogenous 
housekeeping gene, ACTB, and reported as average fold changes ±SEM in agreement with the Comparative ΔΔCt 
Method (please see Experimental Procedures section for a full and detailed description). 
 
FIGURE 2. Decorin potently attenuates VEGFA signaling. A, slot blot analysis of tumor conditioned medium in 
the absence or presence of 500 nM decorin following a 24 h incubation to evaluate effects on secreted VEGFA in 
cervical adenocarcinoma (HeLa), triple negative breast carcinoma (MDA-231), and normal human umbilical vein 
endothelial cells (HUVEC). B, quantification of secreted VEGFA signal intensity for the above described cell lines, 
normalized to total cell number. C, immunoblot analysis of HeLa, MDA-231, and HUVEC cell lysates treated in 
the presence or absence of decorin (500 nM) for 24 h. Lysates were recovered and separated by 10% SDS-PAGE 
and probed for cellular VEGFA. β-actin served as an internal loading control. D, immunoblot quantification 
representing normalized fluorescence to β-actin for cellular VEGFA after decorin protein core treatment. E, slot 
blot analysis of HeLa tumor cell conditioned medium treated with decorin protein core (500 nM) for the indicated 
time points. F, quantification of secreted VEGFA time-course for the time intervals analyzed.  Immunoassayed 
proteins via slot blot and western blot were detected with IR-Dye conjugated secondary antibodies amenable for 
visualization via the Odyssey Infrared Imaging System (LI-COR) with data representative of 2-3 independent 
experiments run in duplicate and reported as mean ±SEM (**p < 0.01, ***p < 0.001)  
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FIGURE 3. Decorin suppresses HIF-1α and VEGFA in constitutively-activated HIF-1α MDA-231 cells under 
normoxic conditions and suppresses critical transcription factors needed for HIF1A and VEGFA expression. 
A,B, immunoblot analysis of HIF-1α expression in either wild-type or mutant cell lines as indicated. Cells were 
exposed for 4 h to increasing concentrations of decorin. The lower parts of the blots were stained with Coomassie 
to demonstrate equal loading. The migration of molecular mass protein standards is shown on the left.  C,D, 
immunolocalization of HIF-1α and VEGFA in either wild-type or mutant cell lines as indicated. The cells were 
treated for 4 h with decorin, fixed, permeabilized and reacted with antibodies specific for either HIF-1α or VEGFA.  
Bar = 10 μm. E, quantification of secreted VEGFA obtained by slot blot analysis of media conditioned for 4 h by 
either wild-type or mutant cells as designated. F, G, gene expression analysis of critical pathway genes found to be 
essential for driving the expression of HIF1A and VEGFA after 4 h (F) or 24 h (G) of decorin as indicated. Data are 
representative of at least two independent trials run in quadruplicate and were normalized to the endogenous house 
keeping gene ACTB. Data are reported as percentage change ±SEM as calculated according to the Comparative 
ΔΔCt Method (*p< 0.05, **p< 0.01, ***p< 0.001).  
 
FIGURE 4. Decorin mediated attenuation of HGF/ Met signaling evokes potent angiostasis. A, immunoblot 
verification of Met protein depletion following transient transfection of cognate targeting siRNA (80 pM) 
(designated as siMet) in HeLa 48 h post transfection. B, immunoblot analysis following positive verification of Met 
knock-down  HeLa lysates probed for cellular VEGFA under conditions of control, decorin (24 h, 500 nM), siMet 
(80 pM), or combined treatment and appear as a quantification of cellular VEGFA fluorescent intensity after 
normalizing to β-actin. C, expression data gained from qPCR analysis of pertinent genes in the presence of siMet 
(80 pM). Verification of siRNA functionality is delineated in this graph for Met. D, HeLa lysates were 
immunoblotted for β-catenin and β-actin (as a loading control) under the influence of decorin (500 nM) for 24 h. E, 
HeLa cDNA libraries evaluated for CTNNB1 via qPCR under the same experimental conditions as in D. F, 
micrographs depicting high resolution digital images of mouse dorsal skin as it appears from the interior, 14 days 
after subcutaneous injection with either Matrigel (80 ml combined with ~106 MDA-231 GFP+ cells) and HGF (10 
ng/ml) in the absence (F, left panel) or presence (F, right panel) of decorin proteoglycan (200 nM). Asterisk 
denotes Matrigel plug and tumor location. G, morphometric analysis of blood vessel density reported as vessel 
intersections per μm2.  Density was calculated by determining the average number of times the newly formed 
angiogenic vessels intersected a grid, representing a standard area of 1mm2, which were superimposed onto the 
images. The values represent the mean ±SEM (n= 600). Bar = 4 mm. Immunoblot and Met knockdown experiments 
represent an average of at least 2 independent experiments performed in duplicate with quantification representing 
the average ± SEM for cellular VEGFA. Gene expression data are a representative of 2-3 independent trials 
reported as fold change ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001).  
 
FIGURE 5. Decorin prevents the expression and activation of matrix metalloproteases necessary for tumor 
extravasation, metastasis, and VEGFA liberation. A, HeLa cell conditioned medium treated with PBS or decorin 
(500 nM) for 24 h was evaluated for enzymatic activity of MMP2 and MMP9 via gelatin zymography. B, 
quantification of MMP9 and MMP2 enzymatic activity as determined in A as a function of relative MMP activity. 
C, HeLa interrogated 24 h post decorin (500 nM) addition for the expression of MMP9 and MMP2 transcripts via 
qPCR. D, ELISA of total MMP9 and MMP2 as indicated and found in HeLa cell conditioned medium (ng/ml/24h) 
in the presence or absence of decorin (500 nM). Gene expression changes are reported as the average fold change ± 
SEM collated over 2-3 trials performed in quadruplicate and normalized to the housekeeping gene ACTB. Gel 
zymography and total MMP2/9 ELISA were repeated twice in triplicate (*p < 0.05, ***p < 0.001). 
 
FIGURE 6. Decorin induces the anti-angiogenic factor, thrombospondin-1 both in cell cultures and in tumor 
xenografts. A,B, media conditioned by HeLa exposed to either vehicle (control) or decorin (500 nM) for 24 h were 
evaluated for the presence of secreted thrombospondin-1 and perlecan (as control). Notice that the levels of 
thrombospondin-1 are significantly elevated by exogenous decorin (***p < 0.001, n=4). The values were obtained 
by utilizing dot blots with serial dilutions of conditioned media (400-12.5 μl) and anti-thrombospondin-1 or anti-
perlecan antibodies and reported as the relative signal intensities of either secreted thrombospondin-1 or perlecan, 
respectively. C, Western blot of cellular thrombospondin-1 from HeLa cells treated with or without decorin as 
indicated. D, tumor volume of HeLa xenografts at day 23. Mice bearing HeLa xenografts were treated with 
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intraperitoneal injections of decorin (5 mg/Kg) every other day over a period of 23 days (***p < 0.001, n=6 per 
group).  E, induction of thrombospondin-1 in the tumor xenografts by systemic delivery of decorin. The images 
show representative frozen sections of HeLa xenografts at day 23 post-decorin treatment or control immunostained 
for thrombospondin-1.  All micrographs were imaged using the same exposure and gain. The right panels are 3D 
surface plots of the corresponding images to the left which were generated with ImageJ software as described 
before (47). Bar ~ 10 μm. F,G, qPCR analysis of mRNA extracted from HeLa xenografts at day 23 post-decorin or 
control treatment. Data are from three independent trials run in quadruplicate and normalized to the endogenous 
house-keeping gene ACTB. (***p< 0.001).  
 
 
FIGURE 7. Schematic representation of proposed model for decorin-evoked angiostatic activity. Please refer to 
the text for a detailed explanation.  
 
 







